Aclarion Inc. Warrant logo

Aclarion Inc. Warrant (ACONW)

Market Closed
6 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
0. 04
+0.01
+20.13%
$
17.65K Market Cap
- P/E Ratio
0% Div Yield
1,235 Volume
- Eps
$ 0.03
Previous Close
Day Range
0.03 0.04
Year Range
0.03 0.2

Summary

ACONW closed yesterday higher at $0.04, an increase of 20.13% from Thursday's close, completing a monthly decrease of -1.62% or $0. Over the past 12 months, ACONW stock lost -47.85%.
ACONW is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track ACONW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

ACONW Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Aclarion Inc. Warrant Dividends

ACONW is not paying dividends to its shareholders.

Aclarion Inc. Warrant Earnings

ACONW have yet to publish their earning reports.
ACONW is not paying dividends to its shareholders.
ACONW have yet to publish their earning reports.

Aclarion Inc. Warrant (ACONW) FAQ

What is the stock price today?

The current price is $0.04.

On which exchange is it traded?

Aclarion Inc. Warrant is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is ACONW.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 17.65K.

Has Aclarion Inc. Warrant ever had a stock split?

No, there has never been a stock split.

Aclarion Inc. Warrant Profile

Medical - Healthcare Information Services Industry
Healthcare Sector
Mr. Brent Ness CEO
NASDAQ (CM) Exchange
655187110 Cusip
US Country
5 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Aclarion, Inc. is a pioneering healthcare technology company based in the United States, focusing on leveraging Magnetic Resonance Spectroscopy (MRS) technology to advance the medical field. MRS is a non-invasive diagnostic technique that provides detailed information about the chemical composition of the body, which is crucial for diagnosing various conditions. Initially founded as Nocimed, Inc. in 2008, the company underwent a significant rebranding, adopting the name Aclarion, Inc. in December 2021. With its headquarters located in Broomfield, Colorado, Aclarion is committed to developing innovative software solutions designed to enhance clinical decision-making processes, particularly in the assessment and management of degenerative pain conditions.

Products and Services

The company has developed the NOCISCAN Post-Processor suite of software applications, which includes two main products:

  • NOCICALC: This software component is crucial for processing the raw, unprocessed MRS exam data. Once it receives this data, NOCICALC post-processes it into final spectra. This process is fundamental as it transforms raw MRS data into a form that can be interpreted and analyzed. Additionally, NOCICALC performs various analyses to identify degenerative pain biomarkers, which are critical for diagnosing and treating pain related to degenerative conditions. Through its sophisticated algorithms, NOCICALC supports healthcare professionals in enhancing their understanding of a patient's condition, enabling more accurate diagnoses and personalized treatment planning.
  • NOCIGRAM: Serving as a clinical decision support software, NOCIGRAM complements the data processing capabilities of NOCICALC by offering actionable insights and recommendations. This software is instrumental in interpreting the processed MRS data, providing clinicians with a comprehensive evaluation of the patient's condition. NOCIGRAM aims to simplify complex data, making it accessible and understandable for medical professionals, which, in turn, assists in making informed and evidence-based clinical decisions. It represents a critical step towards integrating advanced diagnostic technologies into everyday clinical practice, facilitating improved patient outcomes.

Contact Information

Address: 951 Mariners Island Boulevard
Phone: 650-241-1741